209 related articles for article (PubMed ID: 27738108)
1. Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma.
Wang H; Lu J; Edmunds LR; Kulkarni S; Dolezal J; Tao J; Ranganathan S; Jackson L; Fromherz M; Beer-Stolz D; Uppala R; Bharathi S; Monga SP; Goetzman ES; Prochownik EV
J Biol Chem; 2016 Dec; 291(51):26241-26251. PubMed ID: 27738108
[TBL] [Abstract][Full Text] [Related]
2. Myc and ChREBP transcription factors cooperatively regulate normal and neoplastic hepatocyte proliferation in mice.
Wang H; Dolezal JM; Kulkarni S; Lu J; Mandel J; Jackson LE; Alencastro F; Duncan AW; Prochownik EV
J Biol Chem; 2018 Sep; 293(38):14740-14757. PubMed ID: 30087120
[TBL] [Abstract][Full Text] [Related]
3. c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate.
Edmunds LR; Sharma L; Kang A; Lu J; Vockley J; Basu S; Uppala R; Goetzman ES; Beck ME; Scott D; Prochownik EV
J Biol Chem; 2014 Sep; 289(36):25382-92. PubMed ID: 25053415
[TBL] [Abstract][Full Text] [Related]
4. Acquired deficiency of peroxisomal dicarboxylic acid catabolism is a metabolic vulnerability in hepatoblastoma.
Wang H; Lu J; Chen X; Schwalbe M; Gorka JE; Mandel JA; Wang J; Goetzman ES; Ranganathan S; Dobrowolski SF; Prochownik EV
J Biol Chem; 2021; 296():100283. PubMed ID: 33450224
[TBL] [Abstract][Full Text] [Related]
5. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
[TBL] [Abstract][Full Text] [Related]
6. Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.
Dolezal JM; Wang H; Kulkarni S; Jackson L; Lu J; Ranganathan S; Goetzman ES; Bharathi SS; Beezhold K; Byersdorfer CA; Prochownik EV
J Biol Chem; 2017 Jun; 292(24):10068-10086. PubMed ID: 28432125
[TBL] [Abstract][Full Text] [Related]
7. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
[TBL] [Abstract][Full Text] [Related]
8. Myc target miRs and liver cancer: small molecules to get Myc sick.
Buendia MA; Bourre L; Cairo S
Gastroenterology; 2012 Feb; 142(2):214-8. PubMed ID: 22178210
[No Abstract] [Full Text] [Related]
9. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer.
Cairo S; Wang Y; de Reyniès A; Duroure K; Dahan J; Redon MJ; Fabre M; McClelland M; Wang XW; Croce CM; Buendia MA
Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20471-6. PubMed ID: 21059911
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
11. Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant
Comerford SA; Hinnant EA; Chen Y; Bansal H; Klapproth S; Rakheja D; Finegold MJ; Lopez-Terrada D; O'Donnell KA; Tomlinson GE; Hammer RE
JCI Insight; 2016 Oct; 1(16):e88549. PubMed ID: 27734029
[TBL] [Abstract][Full Text] [Related]
12. Abnormal lipid processing but normal long-term repopulation potential of myc-/- hepatocytes.
Edmunds LR; Otero PA; Sharma L; D'Souza S; Dolezal JM; David S; Lu J; Lamm L; Basantani M; Zhang P; Sipula IJ; Li L; Zeng X; Ding Y; Ding F; Beck ME; Vockley J; Monga SP; Kershaw EE; O'Doherty RM; Kratz LE; Yates NA; Goetzman EP; Scott D; Duncan AW; Prochownik EV
Oncotarget; 2016 May; 7(21):30379-95. PubMed ID: 27105497
[TBL] [Abstract][Full Text] [Related]
13. Activation of Wnt and Myc signaling in hepatoblastoma.
Cairo S; Armengol C; Buendia MA
Front Biosci (Elite Ed); 2012 Jan; 4(1):480-6. PubMed ID: 22201888
[TBL] [Abstract][Full Text] [Related]
14. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
Matsumoto S; Yamamichi T; Shinzawa K; Kasahara Y; Nojima S; Kodama T; Obika S; Takehara T; Morii E; Okuyama H; Kikuchi A
Nat Commun; 2019 Aug; 10(1):3882. PubMed ID: 31462641
[TBL] [Abstract][Full Text] [Related]
15. Leptin promotes fatty acid oxidation and OXPHOS via the c-Myc/PGC-1 pathway in cancer cells.
Liu Q; Sun Y; Fei Z; Yang Z; Duan K; Zi J; Cui Q; Yu M; Xiong W
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):707-714. PubMed ID: 31187140
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
17. Patient-Derived Mutant Forms of NFE2L2/NRF2 Drive Aggressive Murine Hepatoblastomas.
Wang H; Lu J; Mandel JA; Zhang W; Schwalbe M; Gorka J; Liu Y; Marburger B; Wang J; Ranganathan S; Prochownik EV
Cell Mol Gastroenterol Hepatol; 2021; 12(1):199-228. PubMed ID: 33618031
[TBL] [Abstract][Full Text] [Related]
18. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL; Rodríguez TC; Mou H; Kwan SY; Pratt H; Zhang XO; Cao Y; Liang S; Ozata DM; Yu T; Yin Q; Hazeltine M; Weng Z; Sontheimer EJ; Xue W
Hepatology; 2021 Mar; 73(3):1011-1027. PubMed ID: 32452550
[TBL] [Abstract][Full Text] [Related]
19. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
Liu R; Li Y; Tian L; Shi H; Wang J; Liang Y; Sun B; Wang S; Zhou M; Wu L; Nie J; Lin B; Tang S; Zhang Y; Wang G; Zhang C; Han J; Xu B; Liu L; Gong K; Zheng T
Cancer Lett; 2019 Feb; 443():34-46. PubMed ID: 30503555
[TBL] [Abstract][Full Text] [Related]
20. CDK9 is dispensable for YAP-driven hepatoblastoma development.
Chen X; Kiss A; Schaff Z; Evert K; Zhang Y; Zhong S; Wang J; Evert M; Calvisi DF; Chen X
Pediatr Blood Cancer; 2020 May; 67(5):e28221. PubMed ID: 32124532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
